

Company Registration No. 05320660 (England and Wales)

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

FRIDAY



A14 *A7FF3DPC* #237
28/09/2018
COMPANIES HOUSE

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

COMPANY INFORMATION

Directors	Mr A Grenfell Mr T Sheppard Mr I Mecci	(Appointed 27 September 2017)
Secretary	Halco Secretaries Limited	
Company number	05320660	
Registered office	210 Pentonville Road London N1 9JY	
Auditor	Ormerod Rutter Limited The Oakley Kidderminster Road Droitwich Worcestershire WR9 9AY	

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

CONTENTS

	Page
Directors' report	1 - 2
Independent auditor's report	3 - 4
Statement of comprehensive income	5
Balance sheet	6
Statement of changes in equity	7
Notes to the financial statements	8 - 15

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

DIRECTORS' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2017

The directors present their annual report and financial statements for the year ended 31 December 2017.

Principal activities

On 1 April 2017 the company sold its trade and net assets to IQVIA World Publications Limited (formerly IMS World Publications Limited), a fellow subsidiary of IQVIA Holdings Inc (formerly IMS Health Holdings Inc), after which the company did not carry out any further trading activities.

The principal activity of the company prior to 1 April 2017 was that of providing medical research data and services.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr A Collier	(Resigned 27 September 2017)
Mr A Grenfell	
Mr R Melia	(Resigned 27 September 2017)
Mr T Sheppard	
Mr I Mecci	(Appointed 27 September 2017)

Results and dividends

The results for the year are set out on page 5.

During the year no interim dividends were paid (2015 - total interim dividends of £2,940,453).

The directors do not recommend the payment of a final dividend.

Auditor

The auditors, Ormerod Rutter Limited, will be proposed for re-appointment in accordance with Section 487(2) of the Companies Act 2006.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

DIRECTORS' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 DECEMBER 2017

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company's auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company's auditor is aware of that information.

In preparing this report the directors have taken advantage of some of the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board



Mr I Mecci

Director

18/09/18

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBER OF IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

Opinion

We have audited the financial statements of IMS Information Solutions Medical Research Limited (the 'company') for the year ended 31 December 2017 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2017 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006;

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's *responsibilities for the audit of the financial statements* section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

These financial statements have not been prepared on a going concern basis for the reason that the company has ceased trading. We have nothing to report in respect of our conclusions relating to going concern as the accounts have been appropriately prepared and the appropriate disclosures have been made. Our opinion is not modified in respect of this matter.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE MEMBER OF IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <http://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Ormerod Rutter Ltd

Colm McGrory FCA (Senior Statutory Auditor)
for and on behalf of Ormerod Rutter Limited

21/9/18

Chartered Accountants
Statutory Auditor

The Oakley
Kidderminster Road
Droitwich
Worcestershire
WR9 9AY

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2017

	Notes	2017 £	2016 £
Turnover		383,282	3,030,817
Cost of sales		(94,178)	(259,150)
Gross profit		289,104	2,771,667
Administrative expenses		(410,657)	(2,454,830)
Staff redundancy costs	3	-	(130,017)
Profit/(loss) on disposal of operations	3	3,072,486	-
Profit before taxation		2,950,933	186,820
Tax on profit	8	6,741	(35,642)
Profit for the financial year		2,957,674	151,178

The Statement of Comprehensive Income has been prepared on the basis that all operations were sold to IQVIA World Publications Limited (formerly IMS World Publications Limited) on 1 April 2017.


IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2017

	Notes	2017 £	£	2016 £	£
Fixed assets					
Tangible assets	9		-		55,772
Current assets					
Debtors	10	3,225,562		869,569	
Cash at bank and in hand		-		1,018,840	
		3,225,562		1,888,409	
Creditors: amounts falling due within one year	11	-		(1,676,293)	
Net current assets		3,225,562		212,116	
Total assets less current liabilities		3,225,562		267,888	
Capital and reserves					
Called up share capital	14	100		100	
Share premium account		6,693		6,693	
Profit and loss reserves		3,218,769		261,095	
Total equity		3,225,562		267,888	

The financial statements were approved by the board of directors and authorised for issue on 18/9/18 and are signed on its behalf by:



Mr I Mecci
Director

Company Registration No. 05320660

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2017

	Share capital £	Share premium account £	Profit and loss reserves £	Total £
Balance at 1 January 2016	100	6,693	109,917	116,710
Year ended 31 December 2016:				
Profit and total comprehensive income for the year	-	-	151,178	151,178
Balance at 31 December 2016	100	6,693	261,095	267,888
Year ended 31 December 2017:				
Profit and total comprehensive income for the year	-	-	2,957,674	2,957,674
Balance at 31 December 2017	100	6,693	3,218,769	3,225,562

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2017

1 Accounting policies

Company information

IMS Information Solutions Medical Research Limited is a private company, limited by shares, registered in England and Wales

The registered office of the company and the principal place of business is 210 Pentonville Road, London, N1 9JY.

1.1 Accounting convention

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The presentational currency of the financial statements is pound sterling.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirement of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirement of Section 33 Related Party Disclosures paragraph 33.7.

1.2 Going concern

On 1 April 2017 the company sold its trade and net assets to IQVIA World Publications UK Limited (formerly IMS World Publications Limited), a fellow subsidiary of IQVIA Holdings Inc (formerly IMS Health Holdings Inc), after which the company did not carry out any further trading activities.

Following the transfer of all assets and activities, these financial statements have been prepared on a non-going concern basis.

1.3 Turnover

Revenue is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Revenue is measured at the fair value of the consideration received, excluding discounts, rebates, VAT and other sales taxes or duty.

Revenue from services provided to customers is recognised by reference to the stage of completion. Where the contract outcome cannot be measured reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

Deferred income reflects the value of sales invoiced in advance of the relating services being provided to the customer.

1.4 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

1 Accounting policies

(Continued)

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	10% on cost
Computers	33% on costs

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is any indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in the income statement.

1.5 Cash and cash equivalents

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.6 Debtors

Short term debtors are measured at transaction price, less any impairment.

Creditors

Short term creditors are measured at transaction price.

1.7 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

1 Accounting policies

(Continued)

1.8 Staff bonus payments

The company recognise the expected cost of bonus payments only when the company has a present legal or constructive obligation to make such payments as a result of past events and a reliable estimate of the obligation can be made.

1.9 Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

1.10 Termination benefits

The company recognise termination benefits as a liability and an expense only when the company is committed either to terminate the employment of an employee or group of employees before the normal retirement date or to provide termination benefits as a result of an offer made in order to encourage voluntary redundancy. The company is committed to a termination only when it has a detailed formal plan for the termination and is without realistic possibility of withdrawal from that plan. The company measures termination benefits at the best estimate of the expenditure that would be required to settle the obligation at the reporting date. In the case of an offer made to encourage voluntary redundancy, the measurement of termination benefits shall be based on the number of employees expected to accept the offer.

1.11 Operating leases

Rentals under operating leases are charged to the profit and loss account over the lease term.

1.12 Foreign exchange

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

2 Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements and estimates. The directors are satisfied that there are no significant judgements or estimates in addition to those that management has made in the process of applying the Company's accounting policies.

3 Exceptional costs/(income)

	2017 £	2016 £
Staff redundancy costs	-	130,017
Profit/(loss) on disposal of operations	(3,072,486)	-

4 Operating profit

	2017 £	2016 £
Operating profit for the year is stated after charging:		
Exchange losses	1,414	1,075
Depreciation of owned tangible fixed assets	4,204	9,596

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

5 Auditor's remuneration

	2017 £	2016 £
Fees payable to the company's auditor and associates:		
For audit services		
Audit of the financial statements of the company	3,000	6,950

6 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2017 Number	2016 Number
Directors	-	1
Employees	3	16
	3	17

Their aggregate remuneration comprised:

	2017 £	2016 £
Wages and salaries	148,096	899,753
Social security costs	24,490	94,754
Pension costs	15,384	45,368
	187,970	1,039,875

Included within gross wages paid in the year are severance pay costs totalling £nil (2016 - £130,017).

7 Directors' remuneration

	2017 £	2016 £
Remuneration for qualifying services	-	105,309
Company pension contributions to defined contribution schemes	-	1,394
	-	106,703

No directors had retirement benefits are accruing under defined contribution schemes (2016 - 1 director had retirement benefits are accruing under defined contribution schemes).

Included in director remunerations are redundancy costs of £nil (2016 - 108,673).

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

8 Taxation

	2017 £	2016 £
Current tax		
UK corporation tax on profits for the current period	-	31,117
Deferred tax		
Origination and reversal of timing differences	(6,871)	3,976
Changes in tax rates	130	549
Total deferred tax	(6,741)	4,525
Total tax (credit)/charge	(6,741)	35,642

The actual (credit)/charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

	2017 £	2016 £
Profit before taxation	2,950,933	186,820
Expected tax charge based on the standard rate of corporation tax in the UK of 19.25% (2016: 20.00%)	568,055	37,364
Tax effect of expenses that are not deductible in determining taxable profit	-	55
Tax effect of income that is not taxable	(591,454)	-
Effect of change in corporation tax rate	130	549
Losses surrendered as group relief for no payment	16,414	-
Other non-reversing timing differences	-	(1,956)
Effect of using a tax rate other than the standard rate for deferred tax	114	(370)
Taxation (credit)/charge for the year	(6,741)	35,642

The tax rate for the current year is lower than the prior year, due to changes in the UK corporation tax rate, which decreased from 20% to 19% from 1 April 2017. Changes to the UK corporation tax rates were substantively enacted as part of Finance Bill 2016 (on 6 September 2016). These include reductions to the main rate to reduce the rate to 17% from 1 April 2020. Deferred taxes at the balance sheet date have been measured using these enacted tax rates and reflected in these financial statements.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

9 Tangible fixed assets

	Fixtures and fittings	Computers	Total
	£	£	£
Cost			
At 1 January 2017	55,903	22,106	78,009
Disposals	(55,903)	(22,106)	(78,009)
At 31 December 2017	-	-	-
Depreciation and impairment			
At 1 January 2017	2,815	19,422	22,237
Depreciation charged in the year	3,153	1,051	4,204
Eliminated in respect of disposals	(5,968)	(20,473)	(26,441)
At 31 December 2017	-	-	-
Carrying amount			
At 31 December 2017	-	-	-
At 31 December 2016	53,088	2,684	55,772

Disposals in the year relate to the sale of all trade and net assets of the company to IQVIA World Publications UK Limited.

10 Debtors

	2017	2016
	£	£
Amounts falling due within one year:		
Trade debtors	-	507,500
Amounts owed by group undertakings	3,225,562	358,779
	3,225,562	866,279
Deferred tax asset (note 12)	-	3,290
	3,225,562	869,569

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

11 Creditors: amounts falling due within one year

	2017 £	2016 £
Trade creditors	-	30,277
Amounts due to group undertakings	-	929,438
Corporation tax	-	31,117
Other taxation and social security	-	2,346
Other creditors	-	545
Accruals and deferred income	-	682,570
	-	1,676,293

12 Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

	Assets 2017 £	Assets 2016 £
Balances:		
Accelerated capital allowances	-	2,340
Accruals	-	950
	-	3,290
Movements in the year:		2017 £
Liability/(Asset) at 1 January 2017		(3,290)
Credit to profit or loss		(6,741)
Transfer to IQVIA World Publications UK Limited		10,031
Liability at 31 December 2017		-

There are no other unrecognised deferred tax balances

The net book value of the company's tangible fixed assets eligible for capital allowances totals £nil (2016 - £55,772) compared to a tax written down value of £nil (2016 - £68,772). The company also has included in its financial statements accruals and provisions totalling £nil (2016 - £5,000) for which tax relief will be obtained in future periods.

The net deferred tax asset amounting to £nil (2016 - £3,290) (calculated at 17% / 19% (2016 - 18% / 19%)) that would arise in respect of these timing differences has been recognised as the directors have assessed that there will be sufficient taxable profits in the group as these timing differences reverse.

IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2017

13 Retirement benefit schemes

	2017	2016
Defined contribution schemes	£	£
Charge to profit or loss in respect of defined contribution schemes	15,384	45,368

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

No contributions were outstanding at the year end (2016 - no contributions outstanding).

14 Share capital

	2017	2016
Ordinary share capital Issued and fully paid	£	£
100 Ordinary shares of £1 each	100	100
	100	100

15 Controlling party

The immediate controlling party is the parent company Pharmadeals Limited.

The company's ultimate parent company, and the parent company of the smallest and largest group to include the company in its consolidated financial statements is IQVIA Holdings Inc, a company registered in the USA and listed on the New York Stock Exchange.

Financial statements of IQVIA Holdings Inc are available from: 83 Wooster Heights Road, Danbury, Connecticut, USA, 06810.